Synthace has raised $74.9M in total across 5 funding rounds.
Synthace's investors include Amadeus Capital Partners, Outsized Ventures, Soffinova Partners, SOSV, Sami Mikati, Sharaf Yamani.
Synthace is a life sciences software company that develops Antha, a no-code digital experiment platform for biology R&D teams. It enables scientists to design, automate, simulate, and analyze reproducible experiments without coding, automatically capturing structured data and metadata to streamline workflows.[1][2][3][6] Serving top pharmaceuticals, biotech firms, CDMOs, and AI innovators, Synthace solves key pain points in bioscience like manual inefficiencies, poor reproducibility, and fragmented tools, accelerating discoveries in health, food, energy, and manufacturing.[1][3][4][5] The platform has driven strong growth, with 94% annual recurring revenue increase, 166% year-on-year total contract value growth, and 170% net revenue retention in its strongest year yet, and is deployed in 10 of the top 20 pharma companies.[3][4]
Founded in 2011 in London, United Kingdom, Synthace emerged at the intersection of software engineering and biological research needs.[2] The company was built by scientists for scientists, addressing frustrations with traditional lab tools that bog down innovation in experiment design and execution.[3][7] Early focus centered on creating Antha as an operating system for biology, linking protocols, equipment, and data into shareable workflows.[1] Pivotal moments include raising $35M in Series C funding to scale its life sciences R&D cloud, expanding U.S. leadership, and gaining adoption by seven of the top 10 global pharma companies, transforming manual processes into automated, collaborative environments.[4]
Synthace rides the wave of digital transformation in biotech R&D, where AI, automation, and cloud computing converge with biology to boost productivity amid rising demands for faster drug discovery and sustainable manufacturing.[1][4] Timing is ideal as life sciences face reproducibility crises and data silos, exacerbated by post-pandemic innovation pressures; Synthace's platform democratizes advanced tools, enabling experiments at scale.[1][3] Market forces like Big Pharma's digital lab investments and biotech funding surges favor it, with competitors like Uncountable and Albert focusing on narrower niches (e.g., materials or data viz).[2] By standardizing workflows and fostering shared protocols, Synthace influences the ecosystem, accelerating collective progress in solving humanity's challenges like health and energy.[1][5][7]
Synthace is poised for explosive growth as life sciences R&D fully embraces no-code platforms and DOE methodologies, with upcoming updates enhancing experiment power and accessibility.[3] Trends like AI-driven biology, global collaboration clouds, and automated biomanufacturing will amplify its edge, potentially capturing more market share from top pharma and emerging biotechs.[4][5] Its influence may evolve from tool provider to ecosystem orchestrator, standardizing "biology as code" and enabling breakthroughs in personalized medicine and sustainability—reinforcing its mission to empower scientists for humanity's toughest problems.[1][7]
Synthace has raised $74.9M across 5 funding rounds. Most recently, it raised $35.0M Series C in November 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2021 | $35.0M Series C | Amadeus Capital Partners, Outsized Ventures, Soffinova Partners, SOSV, Sami Mikati, Sharaf Yamani | |
| Dec 1, 2018 | $26.0M Series B | Outsized Ventures, SOSV | |
| Sep 1, 2017 | $10.0M Series A | Amadeus Capital Partners, Outsized Ventures, SOSV | |
| Dec 1, 2014 | $3.0M Series A | SOSV | |
| Apr 1, 2013 | $900K Seed |
